Jump to content

Pseudoephedrine/loratadine: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
Move interactions to pseudoephedrine; remove merge template
AnomieBOT (talk | contribs)
Bots
6,382,201 edits
m Dating maintenance tags: {{Medcn}} {{Unreferenced section}}
 
(42 intermediate revisions by 31 users not shown)
Line 1: Line 1:
{{Short description|Allergy medicine}}
{{drugbox
{{Use dmy dates|date=July 2024}}
⚫
| verifiedrevid = 437095062
{{cs1 config |name-list-style=vanc |display-authors=6}}
⚫
| type = combo
{{Drugbox
⚫
| component1 = Pseudoephedrine
⚫
| verifiedrevid = 439439973
⚫
| class1 = [[Sympathomimetic]]
⚫
| type = combo
⚫
| component2 = Loratadine

⚫
| class2 = [[H1 antagonist|H<sub>1</sub> antagonist]]
<!--Combo data-->
⚫
| CAS_number =
⚫
| component1 = Pseudoephedrine
⚫
| ATC_prefix = R01
⚫
| class1 = [[Sympathomimetic]]
⚫
| ATC_suffix = BA52
⚫
| component2 = Loratadine
| PubChem =
⚫
| class2 = [[H1 antagonist|H<sub>1</sub> antagonist]]
| DrugBank =

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
<!--Clinical data-->
| pregnancy_US = B
| tradename = Claritin-D, others
⚫
| pregnancy_category=
| Drugs.com = {{Drugs.com|parent|claritin-d}}
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_category =
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| routes_of_administration = [[By mouth]]
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| ATC_prefix = R01
| legal_status = [[Over the counter|OTC]]
⚫
| ATC_suffix = BA52
⚫
| routes_of_administration = Oral

⚫
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = OTC
| legal_US_comment = <ref name="Claritin-D FDA label">{{cite web | title=Claritin-D 12 hour- loratadine and pseudoephedrine sulfate tablet, extended release | website=DailyMed | date=30 November 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7125705-01ff-4418-8c53-9209c2bbb484 | access-date=8 July 2024}}</ref>
| legal_status =

<!--Identifiers-->
⚫
| CAS_number = 156098-07-6

<!--Chemical data-->
}}
}}


'''Pseudoephedrine/loratadine''' (trade names '''Claritin-D''', '''Clarinase''', '''Clarinase Repetabs''') is an orally administered drug combination for the treatment of [[allergic rhinitis]] and the [[common cold]]. [[Pseudoephedrine]], one of the naturally occurring alkaloids of [[ephedra]], is a [[sympathomimetic]] used as a [[decongestant]]. It produces its decongestant effect facilitating [[vasoconstriction]] and shrinkage of congested mucosa in upper respiratory areas. [[Loratadine]] is a long acting [[H1 antagonist|H<sub>1</sub> histamine antagonist]] that is less [[sedating]] than older substances of the type.
'''Pseudoephedrine/loratadine''', sold under the brand name '''Claritin-D''' among others, is an orally administered [[combination drug]] used for the treatment of [[allergic rhinitis]] (hay fever) and the [[common cold]].<ref name="Claritin-D FDA label" /> [[Pseudoephedrine]], one of the naturally occurring alkaloids of [[Ephedra (medicine)|ephedra]], is a [[sympathomimetic]] used as a [[decongestant]].{{medcn|date=July 2024}} It produces a decongestant effect that is facilitated by the [[vasoconstriction]] in the mucosal capillaries of the upper respiratory areas.{{medcn|date=July 2024}} [[Loratadine]] is a long-acting [[antihistamine]] (H<sub>1</sub> histamine antagonist) that is less [[Sedation|sedating]] than older substances of its type.{{medcn|date=July 2024}}


==Medical uses==
==Indications and usage==
Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, [[sneezing]], [[rhinorrhea]], [[pruritus]] and [[lacrimation]].
Pseudoephedrine/loratadine are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, [[sneezing]], [[rhinorrhea]], [[pruritus]], and [[lacrimation]].<ref name="Claritin-D FDA label" /><ref>{{cite book|title=Austria-Codex|at=Clarinase 5&nbsp;mg/120&nbsp;mg Retardtabletten| veditors = Haberfeld H |publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=978-3-85200-196-8|language=German}}</ref>


==Composition==
==Composition==

===Clarinase Repetabs===
===Clarinase Repetabs===
{{unreferenced section|date=July 2024}}
A Clarinase Repetab tablet contains 5&nbsp;mg loratadine in the tablet coating and 120&nbsp;mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.
A Clarinase Repetab tablet contains 5&nbsp;mg loratadine in the tablet coating and 120&nbsp;mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.


Line 35: Line 49:


===Interactions===
===Interactions===
{{unreferenced section|date=July 2024}}
When sympathomimetics are given to patients receiving [[monoamine oxidase inhibitor]]s (MAO inhibitors), hypertensive reactions, including [[hypertensive crises]] may occur.
When sympathomimetics are given to patients receiving [[monoamine oxidase inhibitor]]s (MAO inhibitors), hypertensive reactions, including [[hypertensive crises]] may occur.


===Adverse effects===
===Adverse effects===
{{unreferenced section|date=July 2024}}
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of [[insomnia]] and dry mouth, both of which were commonly reported.
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of [[insomnia]] and dry mouth, both of which were commonly reported.


===Contraindications===
===Contraindications===
{{unreferenced section|date=July 2024}}
Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle [[glaucoma]], urinary retention, severe [[hypertension]], severe [[coronary artery disease]] and [[hyperthyroidism]].
Pseudoephedrine/loratadine is contraindicated in people receiving [[Monoamine oxidase inhibitor|MAO inhibitor]] therapy or within 14 days of discontinuing such treatment and in people with narrow angle [[glaucoma]], urinary retention, severe [[hypertension]], severe [[coronary artery disease]] and [[hyperthyroidism]].

== Society and culture ==
=== Brand names ===
It is sold under various brand names including Claritin-D, Clarinase, Clarinase Repetabs, Lorinase, Rhinos SR, and Allerclear-D.


==References==
==References==
{{reflist}}
* Drugs.com: [http://www.drugs.com/claritin-d.html Claritin-D]
* Israel Ministry of Health: [http://www.health.gov.il/units/pharmacy/trufot/alonim/Clarinase_dr_1250662054911.pdf Clarinase Repetabs]
* {{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2009|edition=2009/2010|isbn=3-85200-196-X|language=German}}


{{Nasal preparations}}
{{Nasal preparations}}
{{Portal bar | Medicine}}
{{Authority control}}


{{DEFAULTSORT:Pseudoephedrine Loratadine}}
[[Category:H1 receptor antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Schering-Plough brands]]
[[Category:Decongestants]]
[[Category:Decongestants]]
[[Category:Combination drugs]]
[[Category:Combination drugs]]

[[ar:كلاريناز]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"